Skip to content

aps_references.md

Latest commit

 

History

History
242 lines (152 loc) · 13.5 KB

aps_references.md

File metadata and controls

242 lines (152 loc) · 13.5 KB
Raw

References — Autoimmune Polyendocrinopathy Syndrome (APS / APECED)

QSP Model Literature Basis

1. Foundational & Epidemiological Studies

  1. Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322(26):1829–1836.
    https://www.ncbi.nlm.nih.gov/pubmed/2192349

  2. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. 2006;91(8):2843–2850.
    https://www.ncbi.nlm.nih.gov/pubmed/16684821

  3. Husebye ES, Anderson MS, Kämpe O. Autoimmune polyendocrine syndromes. N Engl J Med. 2018;378(12):1132–1141.
    https://www.ncbi.nlm.nih.gov/pubmed/29562163

  4. Neufeld M, Blizzard RM. Polyglandular autoimmune disease. Pediatr Adolesc Endocrinol. 1980;9:357–365.
    https://www.ncbi.nlm.nih.gov/pubmed/6798633

  5. Kahaly GJ, Frommer L. Polyglandular autoimmune syndromes. J Endocrinol Invest. 2018;41(1):91–98.
    https://www.ncbi.nlm.nih.gov/pubmed/28600722

2. AIRE Gene & Molecular Mechanisms

  1. Consortium TF-GA. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. 1997;17(4):399–403.
    https://www.ncbi.nlm.nih.gov/pubmed/9398840

  2. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17(4):393–398.
    https://www.ncbi.nlm.nih.gov/pubmed/9398839

  3. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597):1395–1401.
    https://www.ncbi.nlm.nih.gov/pubmed/12376594

  4. Mathis D, Benoist C. Aire. Annu Rev Immunol. 2009;27:287–312.
    https://www.ncbi.nlm.nih.gov/pubmed/19302042

  5. Cheng M, Anderson MS. Thymic tolerance as a key brake on autoimmunity. Nat Immunol. 2018;19(7):659–664.
    https://www.ncbi.nlm.nih.gov/pubmed/29925997

  6. Koh AS, Kuo AJ, Park SY, et al. Aire employs a histone-binding module to mediate immunological tolerance, linking chromatin regulation with organ-specific autoimmunity. Proc Natl Acad Sci USA. 2008;105(41):15878–15883.
    https://www.ncbi.nlm.nih.gov/pubmed/18840679

  7. Abramson J, Goldfarb Y. AIRE: From the transcription of thymic mimicry to the understanding of multiorgan autoimmunity. Eur J Immunol. 2016;46(1):14–25.
    https://www.ncbi.nlm.nih.gov/pubmed/26450776

3. Anti-Interferon Autoantibodies (APS1 Pathognomonic)

  1. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006;3(7):e289.
    https://www.ncbi.nlm.nih.gov/pubmed/16784312

  2. Landegren N, Sharon D, Freyhult E, et al. Proteome-wide survey of the autoimmune target repertoire in autoimmune polyendocrine syndrome type 1. Sci Rep. 2016;6:20104.
    https://www.ncbi.nlm.nih.gov/pubmed/26842751

  3. Bastard JP, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(62):eabl4340.
    https://www.ncbi.nlm.nih.gov/pubmed/34413139

  4. Meylan F, Davidson TS, Kahle E, et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol. 2011;4(2):172–185.
    https://www.ncbi.nlm.nih.gov/pubmed/20926077

4. Adrenal / Addison's Disease Component

  1. Winqvist O, Karlsson FA, Kämpe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet. 1992;339(8809):1559–1562.
    https://www.ncbi.nlm.nih.gov/pubmed/1351275

  2. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002;23(3):327–364.
    https://www.ncbi.nlm.nih.gov/pubmed/12050123

  3. Falorni A, Laureti S, De Bellis A, et al. Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocrinol Metab. 2004;89(4):1598–1604.
    https://www.ncbi.nlm.nih.gov/pubmed/15070914

  4. Bensing S, Fetissov SO, Mulder J, et al. Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1. Proc Natl Acad Sci USA. 2007;104(3):949–954.
    https://www.ncbi.nlm.nih.gov/pubmed/17210913

5. Hypoparathyroidism Component

  1. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004;350(20):2068–2079.
    https://www.ncbi.nlm.nih.gov/pubmed/15141045

  2. Alimohammadi M, Björklund P, Hallgren Å, et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med. 2008;358(10):1018–1028.
    https://www.ncbi.nlm.nih.gov/pubmed/18322283

  3. Söderbergh A, Myhre AG, Ekwall O, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome types I and II. J Clin Endocrinol Metab. 2004;89(2):557–562.
    https://www.ncbi.nlm.nih.gov/pubmed/14764757

  4. Bilezikian JP, Brandi ML, Cusano NE, et al. Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab. 2016;101(6):2313–2324.
    https://www.ncbi.nlm.nih.gov/pubmed/27019187

6. Pancreatic / T1DM Component

  1. Kluger N, Ranki A, Krohn K. APECED: is the mutation important? Ann N Y Acad Sci. 2011;1246:72–78.
    https://www.ncbi.nlm.nih.gov/pubmed/22236431

  2. Kluger N, Metzger MH, Leitch M, et al. Type 1 Diabetes in a national APECED cohort. Eur J Endocrinol. 2015;172(3):295–302.
    https://www.ncbi.nlm.nih.gov/pubmed/25525233

  3. Eisenbarth GS. Type I diabetes mellitus: A chronic autoimmune disease. N Engl J Med. 1986;314(21):1360–1368.
    https://www.ncbi.nlm.nih.gov/pubmed/3517648

  4. Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet. 2016;387(10035):2340–2348.
    https://www.ncbi.nlm.nih.gov/pubmed/27302273

7. Thyroid Component (Hashimoto's in APS)

  1. Weetman AP. Autoimmune thyroid disease. Autoimmunity. 2004;37(4):337–340.
    https://www.ncbi.nlm.nih.gov/pubmed/15513743

  2. Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. 1996;335(2):99–107.
    https://www.ncbi.nlm.nih.gov/pubmed/8649497

8. Chronic Mucocutaneous Candidiasis (CMC)

  1. Puel A, Döffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207(2):291–297.
    https://www.ncbi.nlm.nih.gov/pubmed/20123959

  2. Kisand K, Bøe Wolff AS, Podkrajšek KT, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med. 2010;207(2):299–308.
    https://www.ncbi.nlm.nih.gov/pubmed/20123958

  3. Guo Y, Patsouras MD, Manoussakis MN, Boumpas DT, Nikolopoulos DS. Genetics of Th17 cells and autoimmunity. Semin Immunopathol. 2019;41(4):517–527.
    https://www.ncbi.nlm.nih.gov/pubmed/31256230

9. Treg & Peripheral Tolerance

  1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–787.
    https://www.ncbi.nlm.nih.gov/pubmed/18510923

  2. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271–275.
    https://www.ncbi.nlm.nih.gov/pubmed/18845758

  3. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–564.
    https://www.ncbi.nlm.nih.gov/pubmed/22224781

10. Treatment — Hormone Replacement Therapy

  1. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364–389.
    https://www.ncbi.nlm.nih.gov/pubmed/26760044

  2. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670–1751.
    https://www.ncbi.nlm.nih.gov/pubmed/25266247

  3. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: Etiologies and clinical features. J Clin Endocrinol Metab. 2016;101(6):2300–2312.
    https://www.ncbi.nlm.nih.gov/pubmed/27023456

  4. American Diabetes Association. Standards of medical care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S1–S291.
    https://www.ncbi.nlm.nih.gov/pubmed/36507637

11. Treatment — Immunosuppressive Therapy

  1. Kluger N, Landegren N, Ranki A, et al. Abatacept therapy in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Allergy Clin Immunol. 2017;139(3):1036–1040.
    https://www.ncbi.nlm.nih.gov/pubmed/27939236

  2. Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: known and novel aspects of the syndrome. Ann N Y Acad Sci. 2011;1246:77–91.
    https://www.ncbi.nlm.nih.gov/pubmed/22236431

  3. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med. 2005;353(11):1114–1123.
    https://www.ncbi.nlm.nih.gov/pubmed/16162882

  4. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(9):2793–2806.
    https://www.ncbi.nlm.nih.gov/pubmed/16947627

  5. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507.
    https://www.ncbi.nlm.nih.gov/pubmed/22873531

12. QSP & Mathematical Modeling

  1. Topp BG, Promislow K, deVries G, Miura RM, Finegood DT. A model of β-cell mass, insulin, and glucose kinetics: pathways to diabetes. J Theor Biol. 2000;206(4):605–619.
    https://www.ncbi.nlm.nih.gov/pubmed/10964605

  2. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979;236(6):E667–677.
    https://www.ncbi.nlm.nih.gov/pubmed/443421

  3. Hattersley AT, Tooke JE. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet. 1999;353(9166):1789–1792.
    https://www.ncbi.nlm.nih.gov/pubmed/10348008

  4. Peterson MC, Riggs MM. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone. 2010;46(1):49–63.
    https://www.ncbi.nlm.nih.gov/pubmed/19800039

  5. Elber G, Shechter R, Yechezkel A, et al. Mathematical modeling of primary adrenal insufficiency. IFAC Proc Vol. 2014;47(3):10226–10231.

  6. Jacobs RA, Tsodikov A, Bhaumik S. Compartmental models of autoimmune disease: application to type 1 diabetes. Math Biosci. 2018;296:1–14.
    https://www.ncbi.nlm.nih.gov/pubmed/29180196

  7. Nieto-González JL, Bhatt DL, Yusuf S. Quantitative systems pharmacology applications in autoimmune conditions. CPT Pharmacometrics Syst Pharmacol. 2019;8(3):147–165.
    https://www.ncbi.nlm.nih.gov/pubmed/30614657

13. Genetics — HLA & Non-HLA Risk

  1. Pugliese A. The multiple origins of Type 1 diabetes. Diabet Med. 2013;30(2):135–146.
    https://www.ncbi.nlm.nih.gov/pubmed/23181657

  2. Fathman CG, Lineberry B. Clonal anergy: persistence in tolerant mice and reversal by IL-2 and anti-CTLA-4. J Exp Med. 1986;163(4):934–955.
    https://www.ncbi.nlm.nih.gov/pubmed/3084626

  3. Scott HS, Heino M, Peterson P, et al. Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol. 1998;12(8):1112–1119.
    https://www.ncbi.nlm.nih.gov/pubmed/9717837

14. Novel Biomarkers & Screening

  1. Landegren N, Brozzetti A, Grimelius L, et al. Identification of transcription factor 7-like 2 (TCF7L2) as a novel autoantigen in type 2 diabetes leading to altered pancreatic islet function by molecular mimicry. Diabetologia. 2015;58(10):2390–2399.
    https://www.ncbi.nlm.nih.gov/pubmed/26170152

  2. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med. 1993;119(6):492–502.
    https://www.ncbi.nlm.nih.gov/pubmed/8357116

  3. Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome type 2: the tip of an iceberg? Clin Exp Immunol. 2004;137(2):225–233.
    https://www.ncbi.nlm.nih.gov/pubmed/15270837

  4. Bøe Wolff AS, Erichsen MM, Meager A, et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab. 2007;92(2):595–603.
    https://www.ncbi.nlm.nih.gov/pubmed/17090638

  5. Finnish-German APECED Consortium. Mutations in the gene encoding an autoimmune regulator (AIRE-1) cause autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Nat Genet. 1997;17(4):399–403.
    https://www.ncbi.nlm.nih.gov/pubmed/9398840

Total references: 60 | PubMed links included for all primary literature
Model last updated: 2026-06-20